Lupin receives Health Canada approval for Propranolol Hydrochloride ER capsules

Lupin announced that it has received approval for its Propranolol Hydrochloride Extended-Release (ER) Capsules, 60 mg, 80 mg, 120 mg and 160 mg from Health Canada. Lupin is the first generic company to receive an approval for generic lnderal ® - LA Capsules for the Canadian market and the product has been approved and will be manufactured from Lupin's Pithampur Unit-2 Facility.

Lupin's Propranolol Hydrochloride Extended-Release (ER) Capsules, 60 mg, 80 mg, 120 mg and 160 mg, are the generic version of lnderal® LA Capsules, 60 mg, 80 mg, 120 mg and 160 mg of Pfizer Canada ULC, and are indicated in the treatment of hypertension and for the prophylaxis of angina pectoris.

Powered by Capital Market - Live News